Welcome to our dedicated page for ProKidney news (Ticker: PROK), a resource for investors and traders seeking the latest updates and insights on ProKidney stock.
ProKidney Corp (NASDAQ: PROK) is a clinical-stage biotechnology leader developing autologous cellular therapies for chronic kidney disease. This page provides centralized access to official company announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on PROK's REACT therapy progress, including Phase 3 trial results, regulatory interactions with the FDA/EMA, and manufacturing advancements. Our news collection features earnings reports, partnership announcements, and scientific presentations - all essential for understanding the company's position in regenerative medicine.
The repository includes:
- Clinical trial milestones and data readouts
- Regulatory submissions and designations (including RMAT status)
- Financial performance updates
- Strategic collaborations in nephrology research
- Peer-reviewed study publications
Bookmark this page for verified updates about ProKidney's innovative approach to preserving kidney function through cellular therapy. Check regularly for new developments in this rapidly evolving therapeutic area.
ProKidney Corp. (Nasdaq: PROK) announced its fourth quarter 2022 financial results, reporting a net loss of $24.6 million, compared to $13.7 million in Q4 2021. The company has made significant strides in clinical development, particularly in its REACT® trials for chronic kidney disease, with key milestones anticipated in 2023. Their cash position stands at $490.3 million, bolstered by a PIPE financing that raised over $500 million. R&D expenses rose to $20.9 million, driven by intensified clinical activities. G&A expenses also increased to $9.3 million, influenced by public company costs. The company expects to fund operations through 2024, aiming for topline data from proact1.
ProKidney Corp. (Nasdaq: PROK), a leader in cellular therapeutics for chronic kidney disease (CKD), announced that CEO Dr. Tim Bertram will present at TD Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 10:30 AM EST. Investors can access the live webcast on ProKidney’s investor relations site. The company’s groundbreaking product, REACT™, is a patented therapy aimed at treating late-stage CKD, having received Regenerative Medicine Advanced Therapy designation and FDA guidance. ProKidney, founded in 2015, highlights the critical need for effective CKD treatments, given the high mortality rates associated with late-stage CKD.
ProKidney Corp. (Nasdaq: PROK) announced the publication of early data analysis from its Phase 2 clinical trial, REGEN-003, in the Journal of Blood Purification. The study evaluates the effectiveness of Renal Autologous Cell Therapy (REACT) in patients with late-stage diabetic kidney disease. Participants demonstrated a mean dialysis delay of 16 months, with 20% preserving their kidney function after 15 months. The trial focuses on patients unlikely to qualify for transplants, marking a significant step in CKD treatment. ProKidney emphasizes the potential of REACT to improve quality of life for patients.
ProKidney Corp. (Nasdaq: PROK), a leader in cellular therapeutics for chronic kidney disease (CKD), will have its CEO, Dr. Tim Bertram, present at the J.P. Morgan 41st Annual Healthcare Conference on January 11, 2023, at 3:45 PM PT in San Francisco. The webcast will be accessible via their investor relations website. ProKidney is known for its innovative REACT® therapy aimed at preserving kidney function in late-stage CKD, having received FDA's Regenerative Medicine Advanced Therapy designation. CKD affects over 75 million people in the U.S. and Europe.
ProKidney Corp. (Nasdaq: PROK) announced its Q3 2022 financial results, reporting a net loss of $33.9 million, up from $17.1 million in Q3 2021. The company ended the quarter with $506.3 million in cash, following a successful Nasdaq listing that raised $512 million. ProKidney is advancing its REACT® clinical program, with ongoing Phase 3 studies, proact 1 and proact 2, aimed at chronic kidney disease (CKD) treatment. The company anticipates initial data from its Phase 2 study (REGEN-007) by mid-2023. Significant corporate developments include favorable advice from the EMA and the commencement of patient recruitment in the UK.
ProKidney Corp. (Nasdaq: PROK) announced that CEO Dr. Tim Bertram will participate in upcoming investor conferences, including the Jefferies London Healthcare Conference on November 16, 2022, and the Evercore ISI 5th Annual HEALTHCONx Virtual Conference on December 1, 2022. Both events will feature fireside chats available via webcast on ProKidney’s investor relations website. ProKidney specializes in chronic kidney disease (CKD) treatments, focusing on its groundbreaking REACT® therapy, which has received regulatory designations supporting its Phase 3 clinical program.
ProKidney Corp. (Nasdaq: PROK) announced the approval of its Phase 3 proact 1 study protocol for the REACT® candidate by the UK’s MHRA, following FDA approval in the US. The UK sites will start patient recruitment, expanding the clinical trial beyond North America. ProKidney also received positive feedback from the EMA for its Phase 3 development program, critical for a future MAA. The proact program aims to enroll 600 patients and proactively prevent chronic kidney disease progression. Interim results are expected in late 2024 for proact 1.
ProKidney Corp. (Nasdaq: PROK) announced it will present five posters on chronic kidney disease (CKD) during the ASN Annual Meeting in Orlando, FL, from November 3-6, 2022. Topics include CKD prevalence, gender differences in progression, and the effects of SGLT2 inhibitors. The company will hold an investor briefing on November 3. The lead product candidate, REACT™, aims to slow CKD progression and has received RMAT designation. CKD affects approximately 75 million people in the U.S. and Europe, with significant healthcare costs associated.
